A new study reveals in atomic detail how a blood protein that is a fundamental building block of blood clots gives them their life-enhancing, or life-endangering, properties.
The study, conducted by researchers at the University of Illinois and the Mayo College of Medicine, appears in the journal
Structure.
Fibrinogen molecules form elastic fibers, the main material of blood clots. When a blood vessel is ruptured, signaling proteins in the blood convert fibrinogen into its active form, called fibrin. Fibrin molecules link together in a scaffold of fibers that seals the vesicle. Cells in the blood, such as platelets, fill the gaps.
Fibrinogen is highly elastic, able to reversibly stretch to two or three times its original length.
“Once they’re formed, blood clots have to be elastic because they have a mechanical function to withstand blood pressure,” said Klaus Schulten, holder of the Swanlund Chair in Physics at Illinois.
Understanding what gives fibrinogen its flexibility could help in the design of drugs to enhance their function, he said.
“We investigated what makes blood clots elastic,” said Eric Lee, a graduate research assistant and student in the M.D./Ph.D. program at Illinois. “How do we make them easier to break up or make them less likely to rupture?”
Bernard Lim, a cardiologist at Mayo and an expert on the science of blood clots, contacted Schulten’s group in 2006 for help with a puzzling finding. Lim had conducted a series of experiments using atomic force microscopy to measure the amount of force required to stretch individual fibrinogen molecules.
After dozens of trials, Lim had come up with a “force extension curve” that showed how the fibrinogen molecule behaved when it was stretched. His data indicated that the fibrinogen molecule elongates in a sequential fashion, with three distinct phases. But he could not tell which parts of the fibrinogen molecule were involved.
Fibrinogen is a symmetrical molecule, containing a central region connected to two end regions by long, interweaving coiled chains, called alpha helices. These “coiled coils” were believed to give the molecule its elasticity. But how?
The Illinois team used a computational approach to tackle the mystery. Using steered molecular dynamics (SMD), they modeled the behavior of every atom of the fibrinogen molecule as it was stretched. The computation involved more than a million atoms, and required six months to complete.
The resulting simulation (
see movie) generated a force extension curve that matched the one Lim had produced.
“This was an incredibly strong piece of evidence that what (Lim) saw wasn’t just in the eye of the beholder, but he saw really a property of the protein,” Schulten said.
The simulation also showed in molecular detail how the fibrinogen molecule responded to stretching. Each phase in the force extension curve corresponded directly with a distinct set of events in the elongation of the molecule.
“The simulations revealed that … the extension occurs in a specific and orderly pattern, with distinct regions within the coiled-coil unraveling before others,” the authors wrote.
Lim had also demonstrated that changes in calcium levels or in the pH (acidity) of a blood clot could alter fibrinogen elasticity, a finding that could influence the design of pharmaceutical agents.
“By understanding what happens at the molecular level, you can understand where to target drugs,” Lee said.
This study points to the efficacy of combining molecular dynamics simulations with experimental data on actual molecules, Schulten said. This is proving to be an effective way to get to the heart of molecular behavior, he said.
Simulations can test important, but potentially ambiguous, experimental findings, Schulten said. “And we can see (the behavior of the molecule) in chemical detail, in atomic detail. We see the full chemistry of this mechanical process.”
Source: University of Illinois at Urbana-Champaign
Related stories:
Key found to breakthrough drug for clot victims
A team of researchers at Oregon Health & Science University and Washington University in St. Louis have described for the first time the mechanism that gives a mutant enzyme molecule that they have engineered – and patented – the potential to become a breakthrough drug for treating heart attacks and strokes.
Blood-clotting protein may be new target for Alzheimer's drugs
Despite the rapid rise of Alzheimer’s disease — the Alzheimer’s Association predicts as many as 7.7 million cases by 2030 — there are no preventative treatments available, few in the pharmaceutical pipeline, and those drugs being developed all share the same two molecular targets. Now Rockefeller University researchers report that by targeting a different molecule, a blood-clotting protein called fibrin, they could reduce inflammation in the brains of mice with different models of the disease.
Exploring the molecular origin of blood clot flexibility
How do blood clots maintain that precise balance of stiffness for wound healing and flexibility to go with the flow? Researchers at the University of Pennsylvania School of Medicine and the School of Arts and Sciences have shown that a well-known protein structure acts as a molecular spring, explaining one way that clots may stretch and bend under such physical stresses as blood flow. They report their findings in a Letter in the latest online edition of the Biophysical Journal. This knowledge will inform researchers about clot physiology in such conditions as wound healing, stroke, and cardiovascular disease.
NIST Trumps the Clumps: Making Biologic Drugs Safer
Scientists at the National Institute of Standards and Technology have developed a technique to measure the formation of clumps of proteins in protein-based pharmaceuticals. This first systematic study clarifies the conditions under which scientists can be assured that their instruments are faithfully measuring the formation of protein aggregates, a major concern because of its impact on quality control and safety in biologic drug manufacturing.
Scientists figure out how the immune system and brain communicate to control disease
In a major step in understanding how the nervous system and the immune system interact, scientists at The Feinstein Institute for Medical Research have identified a new anatomical path through which the brain and the spleen communicate. The spleen, once thought to be an unnecessary bit of tissue, is now regarded as an organ where important information from the nervous reaches the immune system. Understanding this process could ultimately lead to treatments that target the spleen to send the right message when fighting human disease.
Viral recombination another way HIV fools the immune system
When individuals infected with HIV become infected with a second strain of the virus, the two viral strains can exchange genetic information, creating a third, recombinant strain of the virus. It is known that the presence of multiple viral strains, called superinfection, frequently leads to a loss of immune control of viral levels. Now a study from the Partners AIDS Research Center at Massachusetts General Hospital (PARC/MGH) shows that how and where viral strains swap DNA may be determined by the immune response against the original infecting strain. Their report will appear in the
Journal of Experimental Medicine and has been released online.
Researchers link Huntington's disease to overactive immune response in the brain
(PhysOrg.com) -- The damage to brain tissue seen in Huntington's disease may be caused by an overactive immune response in the bloodstream and the brain, according to new findings from two teams of researchers at the University of Washington in Seattle and University College London. The findings were published online July 14 in the
Journal of Experimental Medicine.
Gene variant found in those with African ancestry increases odds of HIV infection
A variant of a gene found only in people of African ancestry increases the odds of becoming infected with the human immunodeficiency virus (HIV-1) by 40 percent, according to a long-term study of African Americans reported in the [date] issue of the journal
Cell Host & Microbe, a publication of Cell Press. However, once people are infected, the same variant seems to protect against progression of the disease, allowing those who carry it to live about two years longer.
